You've probably heard – numerous times – that the fictional world of "Jurassic Park" is about to become reality.
And probably every time, after you read the article or listened to the report, the actual innovation was a letdown.
Well, this time, I'm the one telling you that the fictional world of "Jurassic Park" is about to become a reality – and I truly hope what I'm about to tell you isn't a disappointment.
No, I'm not predicting we will see the rebirth of dinosaurs.
But we may soon see formerly extinct species spring to life once again.
Scientists in Australia recently used a cutting-edge gene-editing technique to insert DNA from the passenger pigeon, which went extinct in 1914, into the common pigeon. If all goes as planned, birds from that flock will become the first animals to have genetic codes from an extinct species.
Now that's no letdown and will be, if successful, a huge scientific breakthrough.
There could be a big profit breakthrough here too.
The so-called next-generation sequencing (NGS) market that underpins these breakthroughs will be worth $21.4 billion by 2025, according to Grand View Research.
That would be astounding 362% growth from the $4.62 billion NGS market of 2015.
And you can ride that soaring market with the company I'm going to tell you all about.
The "Pick and Shovel" Play on De-Extinction
The technology behind these Australian researchers' work is known as CRISPR-Cas9.
And it has implications far beyond bringing back passenger pigeons and perhaps other extinct species.
At its most basic level, scientists use this gene-editing technology to precisely modify, delete, or correct disease-causing abnormalities at their genetic sources.
This could have a profound impact on human health – perhaps being the key to the cures for everything from cancer to Alzheimer's to cystic fibrosis. MarketsandMarkets pegs the value of the gene-editing and -engineering sector at $6.4 billion in 2022.
Did You Miss It? Former Speaker John Boehner just joined the cannabis industry’s biggest players to cover everything you need to know about America’s next unstoppable economic revolution. Watch the rebroadcast…
But as exciting as I find this field, there is a challenge for the average retail investor. No doubt, pure plays on CRISPR-Cas9 are higher reward, but they're also higher risk. If that suits your investor profile, I’ve got a play for you – just click here to find out more.
For retail investors looking for a more stable piece of the action in such a profound new field, I suggest putting your money in a rock-solid supplier.
By investing in this "pick and shovel" play, you get both the incredible science and terrific growth in sales and profits.
About the Author
Michael A. Robinson is a 35-year Silicon Valley veteran and one of the top technology financial analysts working today. He regularly delivers winning trade recommendations to the Members of his monthly tech investing newsletter, Nova-X Report, and small-cap tech service, Radical Technology Profits. In the past two years alone, his subscribers have seen over 100 double- and triple-digit gains from his recommendations.
As a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs and high-profile industry insiders. In fact, he was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon. And he was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
In addition to being a regular guest and panelist on CNBC and Fox Business Network, Michael is also a Pulitzer Prize-nominated writer and reporter. His first book, "Overdrawn: The Bailout of American Savings" warned people about the coming financial collapse - years before "bailout" became a household word.
You can follow Michael's tech insight and product updates for free with his Strategic Tech Investor newsletter.